Startups
.............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................
Overview
Location
United States, New Jersey, Boonton
Employees
51-200
Founded date
1983
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 16, 2012 | Oral calcitonin remedy for osteoporosis raises $28M in run-up to its NDA filing | The drug is a peptide hormone that would be destroyed by the digestive system if taken orally, but the technology behind the drug is intended to prevent that from happening. The technology is licensed from Unigene. Under the terms of the ag... |
| Dec 5, 2011 | GSK ends $150M licensing deal with Unigene, cue tough questions | Unigene will be reimbursed by GSK for all invoiced work in connection with the conduct of the study through Nov. 30, according to the statement. Unigene said it expects cash flow to fund business operations into the second half of 2012. In ... |
| Oral calcitonin remedy for osteoporosis raises $28M in run-up to its NDA filing | A therapeutics company has raised $28 million in a series B financing round in the run-up to submitting its new drug application later this year for its oral calcitonin remedy to treat and cure osteoporosis in postmenopausal women. Tarsa Th... | |
| GSK ends $150M licensing deal with Unigene, cue tough questions | Unigene Laboratories is looking for a new partner to commercialize its oral formulation of recombinantly produced parathyroid hormone osteoporosis drug for postmenopausal women after GlaxsoSmithKline (NYSE:GSK) decided to end a nine-year-ol... | |
| Equity analyst hired as Unigene CFO to reduce debt | Unigene Laboratories has hired a chief financial officer as it continues its quest to develop its product pipeline and bring firmer financial footing to the biotechnology company, particularly in reducing its $43 million debt. David Moskowi... |
Reviews 0
FAQ about Unigene Laboratories, Inc.
When was Unigene Laboratories, Inc. founded?
Unigene Laboratories, Inc. was founded in 1983.
What has the press written about Unigene Laboratories, Inc.?
Parsers VC has collected 6 articles mentioning Unigene Laboratories, Inc., among them “Oral calcitonin remedy for osteoporosis raises $28M in run-up to its NDA filing” (Mar 16, 2012) and “GSK ends $150M licensing deal with Unigene, cue tough questions” (Dec 5, 2011).
Is Unigene Laboratories, Inc. still active?
Unigene Laboratories, Inc. is probably closed: its latest activity on Parsers VC dates from Mar 16, 2012.